|

Psilocybin Clinical Trials

21 actively recruiting trials across 12 locations

▼ -3 trials since May 2026

Also known as: 4-phosphoryloxy- N,N-dimethyltryptamine, COMP360, PEX010, Psilocibin, Psilocybin-Assisted Therapy +4 more

Pipeline

Early 1: 1Phase 1: 5Phase 2: 13Phase 3: 1Phase 1/2: 1

Top Sponsors

  • M.D. Anderson Cancer Center2
  • Johns Hopkins University2
  • Yvan Beaussant, MD, MSci1
  • Yale University1
  • University of Washington1

Indications

Other5 trials

A Randomized Neuroimaging Trial of Psilocybin in Depression
Phase 2
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
Phase 1
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)
Phase 1/2
Psilocybin for Hospitalized Patients with Treatment-resistant Depression
Phase 2
Psilocybin for Treatment-Resistant Depression in Autism
Phase 1

Houston, Texas3 trials

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

The University of Texas Health Science Center at Houston

Phase 2
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

MD Anderson Cancer Center

Phase 2
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

The University of Texas M. D. Anderson Cancer Center

Phase 2

Baltimore, Maryland2 trials

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Johns Hopkins Center for Psychedelic and Consciousness Research

Early 1
Psilocybin in Chronic Low Back Pain and Depression

Johns Hopkins University School of Medicine

Phase 1

New York, New York2 trials

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research

Phase 2
Psilocybin-Assisted Therapy for Intergenerational Trauma

The Parsons Research Center for Psychedelic Healing

Phase 2

San Francisco, California1 trial

Psilocybin Therapy for Depression in Parkinson's Disease

University of California, San Francisco

Phase 2

Aurora, Colorado1 trial

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

Outpatient CTRC

Phase 1

Edwards, Colorado1 trial

Investigation to Understand and Optimize Psilocybin

Vail Health Behavioral Health

Phase 2

New Haven, Connecticut1 trial

Open-Label Psilocybin Study in Transdiagnostic Population

Connecticut Mental Health Center - Yale School of Medicine

Phase 1

Boston, Massachusetts1 trial

Psilocybin in Cancer Pain Study

Dana-Farber Cancer Institute

Phase 2

Charlestown, Massachusetts1 trial

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Athinoula A. Martinos Center for Biomedical Imaging

Phase 3

Columbus, Ohio1 trial

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 2

Austin, Texas1 trial

Psilocybin rTMS for Treatment Resistant Depression

Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600

Phase 2

Seattle, Washington1 trial

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.